Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by SanFrancisco99on Mar 19, 2015 8:25pm
217 Views
Post# 23541194

RE:RE:RE:RE:RVX NEW POST BLOG

RE:RE:RE:RE:RVX NEW POST BLOGI'm glad to see that I'm not always the one who parses words this closely in news releases and articles!  LOL

But despite that, I did not read that into this article at all.  Don has said all along (as recently as the February webcast I think) that they were going into the "final stages of planning" the study.  There's nothing new in his saying that.

Because of that, I don't think it means anything more than that they are finishing up the long planning process.  This has been an extended planning process, I think, since they wanted to get things right and had a new guy come on board who will be running the study....  I think I have heard them talk about this fact.

I bet he is glad the process is almost over.

In my view "completing the planning" means that the study will be starting.  They are one and the same thing.  They complete the planning and there's just one thing to do then:  Get it underway with IND filing and then initial dosing.

I bet we are getting quite close to both of those items.

I hope GV can ask them tomorrow about this to clear it  up.







Bullboard Posts